Author

Brian G. Feagan

EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Brian G. Feagan  et al.

INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY
INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY

Brian G. Feagan  et al.

PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION
PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION

Brian G. Feagan  et al.

ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS
ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS

Brian G. Feagan  et al.

EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Brian G. Feagan  et al.

EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL
EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL

Brian G. Feagan  et al.

INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS

Brian G. Feagan  et al.

TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY
TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY

Brian G. Feagan  et al.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

Brian G. Feagan  et al.

TL1A BLOCKADE BY PRA023 LEADS TO REDUCTION OF INFLAMMATORY AND FIBROTIC PATHWAYS IN PATIENTS WITH CROHN’S DISEASE
TL1A BLOCKADE BY PRA023 LEADS TO REDUCTION OF INFLAMMATORY AND FIBROTIC PATHWAYS IN PATIENTS WITH CROHN’S DISEASE

Brian G. Feagan  et al.

ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY
ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY

Brian G. Feagan  et al.

RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Brian G. Feagan  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Brian G. Feagan  et al.

THE EFFICACY OF INDUCTION TREATMENT WITH GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12 BY PRIOR ADVANCED THERAPY HISTORY
THE EFFICACY OF INDUCTION TREATMENT WITH GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12 BY PRIOR ADVANCED THERAPY HISTORY

Brian G. Feagan  et al.

OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Brian G. Feagan  et al.

IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Brian G. Feagan  et al.

HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY
HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY

Brian G. Feagan  et al.

ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL
ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL

Brian G. Feagan  et al.

CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL
CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL

Brian G. Feagan  et al.

PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY
PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY

Brian G. Feagan  et al.

Item 41 - 60 / 77
1 2
3
4